trending Market Intelligence /marketintelligence/en/news-insights/trending/2e-LV7-EkU-Ja0BqQ7D6zQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Avadel's hospital product candidate accepted for priority review by US FDA

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Avadel's hospital product candidate accepted for priority review by US FDA

Avadel Pharmaceuticals PLC said the U.S. Food and Drug Administration accepted the new drug application for the company's hospital product candidate AV001 and granted it priority review.

The U.S. regulator will decide on Avadel's product candidate by Sept. 15. The Dublin-based company did not disclose what indication the product will be used for.